-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Malignant pleural mesothelioma is a rare tumor with increasing global incidence and poor prognosis.
Malignant pleural mesothelioma is a rare tumor with increasing global incidence and poor prognosis.
The study was carried out in 26 hospitals in Italy and recruited patients who were 18 years of age or older, had an ECOG performance status of 0-2, confirmed histologically, and had progressed during or after platinum+pemetrexed first-line treatment.
Overall survival and progression-free survival of the two groups of patients
Overall survival and progression-free survival of the two groups of patientsFrom December 22, 2016 to July 30, 2018, a total of 161 patients received gemcitabine + placebo (n=81) or gemcitabine + ramucirumab (n=80) treatment
The overall survival time of the ramucirumab group was longer than that of the placebo group, and the median overall survival time was 13.
The occurrence of adverse events
The occurrence of adverse eventsThirty-five (44%) and 24 (30%) patients in the ramucirumab group and placebo group respectively reported grade 3-4 treatment-related adverse events
In summary, for patients with malignant pleural mesothelioma who have progressed after standard chemotherapy treatment, ramucirumab combined with gemcitabine can significantly prolong their overall survival compared with gemcitabine monotherapy, and has good safety
For patients with malignant pleural mesothelioma that progressed after standard chemotherapy, ramucirumab combined with gemcitabine can significantly prolong their overall survival compared with gemcitabine monotherapy, and the safety is good.
Original source:
Carmine Pinto, et al.
Gemcitabine with or without ramucirumab as second- line treatment for malignant pleural mesothelioma (RAMES): a randomised, double-blind, placebo-controlled, phase 2 trial
in this message
